The Utility of Ablative Radiotherapy in Metastatic Breast Cancer
Julia White, MD, from The Ohio State University Comprehensive Cancer Center, discusses the utility of ablative radiotherapy in metastatic breast cancer.
Clinical Pearls
Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, discusses the utility of ablative radiotherapy in metastatic breast cancer.
- An ablative radiotherapy approach to metastatic regions allows for the avoidance of a surgical procedure.
- Though surgical procedures are typically well tolerated, there are inherent risks associated with anesthesia and complications following surgery.
- Patients must stop systemic therapy in order to undergo surgery. With an ablative radiotherapy approach, there are no treatment interruptions.
Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer
December 22nd 2024During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for patients with hormone receptor–positive breast cancer.
Read More
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
